Connect with us

Life Sciences

Enosis and OVID Clinics partner to offer VR-modulated psychedelic therapy in Berlin

The companies claim this will be the ‘world’s first’ in-clinic application of VR with psychedelic-assisted therapy
The post Enosis and OVID Clinics partner…

Published

on

This article was originally published by Mugglehead

Enosis Therapeutics — an Australian psychedelic start-up — has been pioneering a new variety of psychedelic therapy involving modern technology with the help of a German healthcare company.

On Monday, the company announced that it had entered into a partnership with OVID Clinics to help implement what it believes is the world’s first in-clinic application of psychedelic therapy in conjunction with virtual reality.

OVID Clinics is a Berlin-based healthcare services provider that will now be giving patients the option to experience psychedelics in combination with the so-called science-backed virtual technology protocols from Enosis.

Enosis and Ovid Clinics partner to offer VR-modulated psychedelic therapy in Berlin

Milosz Marganski, VR Lead at Enosis. Photo via Enosis Therapeutics.

Read more: Spirit Plant Medicine Conference returns at UBC to discuss psychedelics and consciousness

Read more: Algernon partners with Yale University for phase II DMT study

The news follows positive results obtained by Enosis through research conducted this June in partnership with Swinburne University of Technology in Australia. High levels of “acceptance and satisfaction” were reported by participants who had experienced a combination of psychedelic therapy and VR during the course of the study, which has inspired Enosis to begin offering its unorthodox variety of therapy at OVID Clinics.

“Enhancing patient accessibility to our VR experiences remains our top priority and we are excited to bring this novel treatment to patients in need. Together with the OVID team, our focus is to achieve positive patient outcomes and longer-lasting therapeutic benefits for patients battling mental health illnesses,” said Agnieszka D. Sekula, Co-Founder of Enosis Therapeutics.

Enosis says that the partnership with OVID proves that VR is an efficacious technology for improving mental health and that the technology’s protocols and capabilities are steadily gaining momentum in psychedelic studies and clinical environments.

Enosis added that patient enrollment is currently in progress.

“We are convinced that this partnership will help innovate the field by shifting the focus from the psychedelic substance to the psychedelic experience and its integration, supporting patients in every step of the way through their journey into well-being,” said Sergio Pérez Rosal, Co-Founder and CEO of OVID Clinics.

 

Follow Mugglehead on Twitter

Like Mugglehead on Facebook

 

 

 

 

 

The post Enosis and OVID Clinics partner to offer VR-modulated psychedelic therapy in Berlin appeared first on Mugglehead Magazine.

therapeutics


application
therapy
dmt

Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending